{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T07:41:28Z","timestamp":1791272488551,"version":"4.1.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2014,11,1]],"date-time":"2014-11-01T00:00:00Z","timestamp":1414800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,11,1]],"date-time":"2014-11-01T00:00:00Z","timestamp":1414800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","maturitas.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Maturitas"],"published-print":{"date-parts":[[2014,11]]},"DOI":"10.1016\/j.maturitas.2014.07.007","type":"journal-article","created":{"date-parts":[[2014,7,16]],"date-time":"2014-07-16T16:21:08Z","timestamp":1405527668000},"page":"241-247","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Use of FRAX\u00ae-based fracture risk assessments to identify patients who will benefit from osteoporosis therapy"],"prefix":"10.1016","volume":"79","author":[{"given":"Stuart L.","family":"Silverman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry S.","family":"Komm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Mirkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl. 6","key":"10.1016\/j.maturitas.2014.07.007_bib0005","first-page":"S164","article-title":"Osteoporosis and the burden of osteoporosis-related fractures","volume":"17","author":"Dempster","year":"2011","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.maturitas.2014.07.007_bib0010","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s11657-011-0060-1","article-title":"Osteoporosis: burden, health care provision and opportunities in the EU: a report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA)","volume":"6","author":"Strom","year":"2011","journal-title":"Arch Osteoporos"},{"key":"10.1016\/j.maturitas.2014.07.007_bib0015","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1001\/jama.2009.50","article-title":"Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women","volume":"301","author":"Bliuc","year":"2009","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.maturitas.2014.07.007_bib0020","first-page":"21","article-title":"Osteoporotic fractures: mortality and quality of life","volume":"49","author":"Caliri","year":"2007","journal-title":"Panminerva Med"},{"key":"10.1016\/j.maturitas.2014.07.007_bib0025","first-page":"618","article-title":"Mortality and functional impairment after hip fracture \u2013 a prospective study in a Portuguese population","volume":"34","author":"da Costa","year":"2009","journal-title":"Acta Reumatol Port"},{"key":"10.1016\/j.maturitas.2014.07.007_bib0030","first-page":"181","article-title":"Osteoporosis management in post-menopausal women","volume":"64","author":"Christenson","year":"2012","journal-title":"Minerva Ginecol"},{"key":"10.1016\/j.maturitas.2014.07.007_bib0035","doi-asserted-by":"crossref","unstructured":"North American Menopause Society. Management of osteoporosis in postmenopausal women: 2010 position statement of The North American Menopause Society. Menopause 2010;17:25\u201354.","DOI":"10.1097\/gme.0b013e3181c617e6"},{"key":"10.1016\/j.maturitas.2014.07.007_bib0040","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.jbspin.2008.09.002","article-title":"Predicting the fracture risk in 2008","volume":"75","author":"Fardellone","year":"2008","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.maturitas.2014.07.007_bib0045","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.ejrad.2008.04.061","article-title":"Assessment of fracture risk","volume":"71","author":"Kanis","year":"2009","journal-title":"Eur J Radiol"},{"key":"10.1016\/j.maturitas.2014.07.007_bib0050","series-title":"Assessment of osteoporosis at the primary health-care level. Technical report","author":"Kanis","year":"2007"},{"key":"10.1016\/j.maturitas.2014.07.007_bib0055","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.bone.2009.01.373","article-title":"FRAX and its applications to clinical practice","volume":"44","author":"Kanis","year":"2009","journal-title":"Bone"},{"key":"10.1016\/j.maturitas.2014.07.007_bib0060","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1089\/jwh.2010.2294","article-title":"The Fracture Risk Assessment Tool (FRAX(R)): applications in clinical practice","volume":"20","author":"Watts","year":"2011","journal-title":"J Womens Health (Larchmt)"},{"key":"10.1016\/j.maturitas.2014.07.007_bib0065","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1359\/jbmr.090402","article-title":"FRAX facts","volume":"24","author":"Watts","year":"2009","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.maturitas.2014.07.007_bib0070","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1007\/s11914-010-0032-1","article-title":"The utility and limitations of FRAX: a US perspective","volume":"8","author":"Silverman","year":"2010","journal-title":"Curr Osteoporos Rep"},{"key":"10.1016\/j.maturitas.2014.07.007_bib0075","series-title":"Clinician's guide to prevention and treatment of osteoporosis","author":"National Osteoporosis Foundation","year":"2013"},{"key":"10.1016\/j.maturitas.2014.07.007_bib0080","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1007\/s00198-008-0712-1","article-title":"Case finding for the management of osteoporosis with FRAX \u2013 assessment and intervention thresholds for the UK","volume":"19","author":"Kanis","year":"2008","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.maturitas.2014.07.007_bib0085","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1002\/jbmr.1582","article-title":"Does osteoporosis therapy invalidate FRAX for fracture prediction","volume":"27","author":"Leslie","year":"2012","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.maturitas.2014.07.007_bib0090","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/j.bone.2009.02.014","article-title":"Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX","volume":"44","author":"Kanis","year":"2009","journal-title":"Bone"},{"key":"10.1016\/j.maturitas.2014.07.007_bib0095","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1002\/jbmr.1625","article-title":"Effect of alendronate for reducing fracture by FRAX score and femoral neck bone mineral density: the Fracture Intervention Trial","volume":"27","author":"Donaldson","year":"2012","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.maturitas.2014.07.007_bib0100","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.bone.2010.06.009","article-title":"A meta-analysis of the efficacy of raloxifene on all clinical and vertebral fractures and its dependency on FRAX","volume":"47","author":"Kanis","year":"2010","journal-title":"Bone"},{"key":"10.1016\/j.maturitas.2014.07.007_bib0105","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1007\/s00198-010-1474-0","article-title":"A meta-analysis of the effect of strontium ranelate on the risk of vertebral and non-vertebral fracture in postmenopausal osteoporosis and the interaction with FRAX((R))","volume":"22","author":"Kanis","year":"2011","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.maturitas.2014.07.007_bib0110","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1007\/s00198-008-0786-9","article-title":"Ten-year fracture probability identifies women who will benefit from clodronate therapy \u2013 additional results from a double-blind, placebo-controlled randomised study","volume":"20","author":"McCloskey","year":"2009","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.maturitas.2014.07.007_bib0115","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1002\/jbmr.1606","article-title":"Denosumab reduces the risk of osteoporotic fractures in postmenopausal women, particularly in those with moderate to high fracture risk as assessed with FRAX","volume":"27","author":"McCloskey","year":"2012","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.maturitas.2014.07.007_bib0120","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1007\/s00198-013-2341-6","article-title":"An evaluation of the Fracture Risk Assessment Tool (FRAX) as an indicator of treatment efficacy: the effects of bazedoxifene and raloxifene on vertebral, nonvertebral, and all clinical fractures as a function of baseline fracture risk assessed by FRAX","volume":"24","author":"Kaufman","year":"2013","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.maturitas.2014.07.007_bib0125","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1177\/1759720X11422602","article-title":"Bazedoxifene: the evolving role of third-generation selective estrogen-receptor modulators in the management of postmenopausal osteoporosis","volume":"4","author":"Komm","year":"2012","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"10.1016\/j.maturitas.2014.07.007_bib0130","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1359\/jbmr.080710","article-title":"Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial","volume":"23","author":"Silverman","year":"2008","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.maturitas.2014.07.007_bib0135","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1001\/jama.282.7.637","article-title":"Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators","volume":"282","author":"Ettinger","year":"1999","journal-title":"J Am Med Assoc"},{"issue":"Suppl. 1","key":"10.1016\/j.maturitas.2014.07.007_bib0140","first-page":"S10","article-title":"Efficacy of alendronate for reducing nonvertebral and clinical fractures by FRAX score [abstract 1030]","volume":"24","author":"Cummings","year":"2009","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.maturitas.2014.07.007_bib0145","doi-asserted-by":"crossref","first-page":"3999","DOI":"10.1210\/en.2005-0030","article-title":"Bazedoxifene acetate: a selective estrogen receptor modulator with improved selectivity","volume":"146","author":"Komm","year":"2005","journal-title":"Endocrinology"},{"key":"10.1016\/j.maturitas.2014.07.007_bib0150","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1248\/cpb.c13-00710","article-title":"Thermodynamic evaluation of the binding of bisphosphonates to human farnesyl pyrophosphate synthase","volume":"62","author":"Kawasaki","year":"2014","journal-title":"Chem Pharm Bull (Tokyo)"},{"key":"10.1016\/j.maturitas.2014.07.007_bib0155","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s00223-013-9711-0","article-title":"In vitro and in vivo responses to high and low doses of nitrogen-containing bisphosphonates suggest engagement of different mechanisms for inhibition of osteoclastic bone resorption","volume":"92","author":"Fisher","year":"2013","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.maturitas.2014.07.007_bib0160","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1002\/jbmr.1854","article-title":"Goal-directed treatment of osteoporosis","volume":"28","author":"Cummings","year":"2013","journal-title":"J Bone Miner Res"}],"container-title":["Maturitas"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378512214002369?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378512214002369?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T09:00:49Z","timestamp":1759914049000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0378512214002369"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,11]]}},"alternative-id":["S0378512214002369"],"URL":"https:\/\/doi.org\/10.1016\/j.maturitas.2014.07.007","relation":{},"ISSN":["0378-5122"],"issn-type":[{"value":"0378-5122","type":"print"}],"subject":[],"published":{"date-parts":[[2014,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Use of FRAX\u00ae-based fracture risk assessments to identify patients who will benefit from osteoporosis therapy","name":"articletitle","label":"Article Title"},{"value":"Maturitas","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.maturitas.2014.07.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}